The management of status epilepticus

Chest

Volumn 126, Issue 2, 2004, Pages 582-591

  Marik, Paul E ^a,c   Varon, Joseph ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsants; Barbiturates; Lorazepam; Midazolam; Phenytoin; Propofol; Refractory status epilepticus; Status epilepticus

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID C RECEPTOR; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; DIAZEPAM; ETOMIDATE; FOSPHENYTOIN SODIUM; GLUCOSE; ISOFLURANE; KETAMINE; LIDOCAINE; LORAZEPAM; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; ROCURONIUM; THIAMINE; THIOPENTAL; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG HALF LIFE; DRUG INDUCED DISEASE; ENDOTRACHEAL INTUBATION; EPILEPTIC STATE; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPOFOL INFUSION SYNDROME; REVIEW; TACHYPHYLAXIS;

EID: 4143138684     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.2.582     Document Type: Review

References (111)

1. Logroscino G, Hesdorffer DC, Cascino GD, et al. Long-term mortality after a first episode of status epilepticus. Neurology 2002; 58:537-541
2. Epilepsy Foundation of America. Treatment of convulsive status epilepticus: recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270:854-859
3. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998; 338:970-976
4. Chapman MG, Smith M, Hirsch NP. Status epilepticus. Anaesthesia 2001; 56:648-659
5. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40:120-122
6. DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia 1999; 40:164-169
7. Walton NY, Treiman DM. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp Neurol 1988; 101:267-275
8. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205-210
9. Treiman DM, Meyers PD, Walton NY. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339:792-798
10. Prasad A, Worrall BB, Bertram EH, et al. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42:380-386
11. Bleck TP. Management approaches to prolonged seizures and status epilepticus. Epilepsia 1999; 40(suppl):S59-S63
12. Browne TR, Holmes GL. Epilepsy. N Engl J Med 2001; 344:1145-1151
13. DeLorenzo RJ, Pellock JM, Towne AR, et al. Epidemiology of status epilepticus. J Clin Neurophysiol 1995; 12:316-325
14. Wu YW, Shek DW, Garcia PA, et al. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002; 58:1070-1076
15. Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998; 50:735-741
16. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001; 42:714-718
17. DeGiorgio CM, Altman K, Hamilton-Byrd E, et al. Lidocaine in refractory status epilepticus: confirmation of efficacy with continuous EEG monitoring. Epilepsia 1992; 33:913-916
18. Coeytaux A, Jallon P, Galobardes B, et al. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000; 55:693-697
19. Parviainen I, Uusaro A, Kalviainen R, et al. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology 2002; 59:1249-1251
20. Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990; 40:9-13
21. Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology 2000; 55:S9-S14
22. Lowenstein DH, Alldredge BK, Allen F, et al. The prehospital treatment of status epilepticus (PHTSE) study: design and methodology. Control Clin Trials 2001; 22:290-309
23. Alldredge BK, Lowenstein DH. Status epilepticus: new concepts. Curr Opin Neurol 1999; 12:183-190
24. Corey LA, Pellock JM, Boggs JG, et al. Evidence for a genetic predisposition for status epilepticus. Neurology 1998; 50:558-560
25. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345:631-637
26. Dennis LJ, Claassen J, Hirsch LJ, et al. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery 2002; 51:1136-1143
27. Krieger AC, Takeyasu M. Nonconvulsive status epilepticus in theophylline toxicity. J Toxicol Clin Toxicol 1999; 37:99-101
28. Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000; 54:340-345
29. Rumbach L, Sablot D, Berger E, et al. Status epilepticus in stroke: report on a hospital-based stroke cohort. Neurology 2000; 54:350-354
30. Dixit S, Kurle P, Buyan-Dent L, et al. Status epilepticus associated with cefepime. Neurology 2000; 54:2153-2155
31. Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 2001; 111:115-119
32. Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. Neurology 2001; 57:200-206
33. Boggs JG, Painter JA, DeLorenzo RJ. Analysis of electrocardiographic changes in status epilepticus. Epilepsy Res 1993; 14:87-94
34. Rice AC, DeLorenzo RJ. NMDA receptor activation during status epilepticus is required for the development of epilepsy. Brain Res 1998; 782:240-247
35. Pal S, Sombati S, Limbrick DD Jr, et al. In vitro status epilepticus causes sustained elevation of intracellular calcium levels in hippocampal neurons. Brain Res 1999; 851:20-31
36. Bleck TP. Refractory status epilepticus in 2001. Arch Neurol 2002; 59:188-189
37. Kapur J, Stringer JL, Lothman EW. Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition. J Neurophysiol 1989; 61:417-426
38. Kapur J, Lothman EW. Loss of inhibition precedes delayed spontaneous seizures in the hippocampus after tetanic electrical stimulation. J Neurophysiol 1989; 61:427-434
39. Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997; 17:7532-7540
40. Walton NY, Treiman DM. Motor and electroencephalographic response of refractory experimental status epilepticus in rats to treatment with MK-801, diazepam, or MK-801 plus diazepam. Brain Res 1991; 553:97-104
41. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000; 42:117-122
42. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993; 341:1607-1610
43. Lowenstein DH, Simon RP, Sharp FR. The pattern of 72-kDa heat shock protein-like immunoreactivity in the rat brain following flurothyl-induced status epilepticus. Brain Res 1990; 531:173-182
44. Tanaka K, Graham SH, Simon RP. The role of excitatory neurotransmitters in seizure-induced neuronal injury in rats. Brain Res 1996; 737:59-63
45. Meldrum BS, Brierley JB. Prolonged epileptic seizures in primates: ischemic cell change and its relation to ictal physiological events. Arch Neurol 1973; 28:10-17
46. Nevander G, Ingvar M, Auer R, et al. Status epilepticus in well-oxygenated rats causes neuronal necrosis. Ann Neurol 1985; 18:281-290
47. Wasterlain CG, Fujikawa DG, Penix L, et al. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993; 34(suppl):S37-S53
48. DeGiorgio CM, Gott PS, Rabinowicz AL, et al. Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. Epilepsia 1996; 37:606-609
49. Rabinowicz AL, Correale JD, Bracht KA, et al. Neuron-specific enolase is increased after nonconvulsive status epilepticus. Epilepsia 1995; 36:475-479
50. Rabinowicz AL, Correale JD, Couldwell WT, et al. CSF neuron-specific enolase after methohexital activation during electrocorticography. Neurology 1994; 44:1167-1169
51. DeGeorgio CM, Correale JD, Ginsburg DL. Serum neuron specific enolase in status epilepticus [abstract]. Neurology 1994; 44(suppl):205
52. Thom M, Seetah S, Sisodiya S, et al. Sudden and unexpected death in epilepsy (SUDEP): evidence of acute neuronal injury using HSP-70 and c-Jun immunohistochemistry. Neuropathol Appl Neurobiol 2003; 29:132-143
53. Mikati MA, Abi-Habib RJ, El Sabban ME, et al. Hippocampal programmed cell death after status epilepticus: evidence for NMDA-receptor and ceramide-mediated mechanisms. Epilepsia 2003; 44:282-291
54. Lothman E. THe biochemical basis and pathophysiology of status epilepticus. Neurology 2003; 40(suppl):13-23
55. Coplin WM, Pierson DJ, Cooley KD, et al. Implications of extubation delay in brain-injured patients meeting standard weaning criteria. Am J Respir Crit Care Med 2000; 161:1530-1536
56. Yeoman P, Hutchinson A, Byrne A, et al. Etomidate infusions for the control of refractory status epilepticus. Intensive Care Med 1989; 15:255-259
57. Wauquier A. Profile of etomidate: a hypnotic, anticonvulsant and brain protective compound. Anaesthesia 1983; 38(suppl):26-33
58. Marshall RJ, Muir AW, Sleigh T, et al. An overview of the pharmacology of rocuronium bromide in experimental animals. Eur J Anaesthesiol Suppl 1994; 9:9-15
59. Hudson ME, Rothfield KP, Tullock WC, et al. Haemodynamic effects of rocuronium bromide in adult cardiac surgical patients. Can J Anaesth 1998; 45:139-143
60. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249:1452-1454
61. Mitchell WG. Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Epilepsia 1996; 37(suppl):S74-S80
62. Gottwald MD, Akers LC, Liu PK, et al. Prehospital stability of diazepam and lorazepam. Am J Emerg Med 1999; 17:333-337
63. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39:833-840
64. Claassen J, Hirsch LJ, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43:146-153
65. Koul RL, Raj AG, Chacko A, et al. Continuous midazolam infusion as treatment of status epilepticus. Arch Dis Child 1997; 76:445-448
66. Igartua J, Silver P, Maytal J, et al. Midazolam coma for refractory status epilepticus in children. Crit Care Med 1999; 27:1982-1985
67. Ulvi H, Yoldas T, Mungen B, et al. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci 2002; 23:177-182
68. Singhi S, Murthy A, Singhi P, et al. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol 2002; 17:106-110
69. Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000; 54:1366-1368
70. Claassen J, Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001; 57:1036-1042
71. Stecker MM, Kramer TH, Raps EC, et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39:18-26
72. Harrison AM, Lugo RA, Schunk JE. Treatment of convulsive status epilepticus with propofol: case report. Pediatr Emerg Care 1997; 13:420-422
73. Merigian KS, Browning RG, Leeper KV. Successful treatment of amoxapine-induced refractory status epilepticus with propofol. Acad Emerg Med 1995; 2:128-133
74. Tobias JD. The use of propofol to treat status epilepticus in a nine-month-old female patient. Pediatr Emerg Care 1998; 14:248-249
75. Pitt-Miller PL, Elcock BJ, Maharaj M. The management of status epilepticus with a continuous propofol infusion. Anesth Analg 1994; 78:1193-1194
76. Campostrini R, Bati MB, Giorgi C, et al. Propofol in the treatment of convulsive status epilepticus: a report of four cases. Riv Neurol 1991; 61:176-179
77. Mackenzie SJ, Kapadia F, Grant IS. Propofol infusion for control of status epilepticus. Anaesthesia 1990; 45:1043-1045
78. Hall RI, Sandham D, Cardinal P, et al. Propofol vs midazolam for ICU sedation: a Canadian multicenter randomized trial. Chest 2001; 119:1151-1159
79. Smith I, White PF, Nathanson M, et al. Propofol: an update on its clinical use. Anesthesiology 1994; 81:1005-1043
80. Hara M, Kai Y, Ikemoto Y. Propofol activates GABAA receptor-chloride ionophore complex in dissociated hippocampal pyramidal neurons of the rat. Anesthesiology 1993; 79:781-788
81. Orser BA, Bertlik M, Wang LY, et al. Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br J Pharmacol 1995; 116:1761-1768
82. Hans P, Bonhomme V, Collette J, et al. Propofol protects cultured rat hippocampal neurons against N-methyl-D-aspartate receptor-mediated glutamate toxicity. J Neurosurg Anesthesiol 1994; 6:249-253
83. Zhou W, Fontenot J, Liu S, et al. Modulation of cardiac calcium channels by propofol. Anesthesiology 1997; 86:670-675
84. Olcese R, Usai C, Maestrone E, et al. The general anesthetic propofol inhibits transmembrane calcium current in chick sensory neurons. Anesth Analg 1994; 78:955-960
85. Green TR, Bennett SR, Nelson VM. Specificity and properties of propofol as an antioxidant free radical scavenger. Toxicol Appl Pharmacol 1994; 129:163-169
86. Tsuchiya M, Asada A, Maeda K, et al. Propofol versus midazolam regarding their antioxidant activities. Am J Respir Crit Care Med 2001; 163:26-31
87. Grasshoff C, Gillessen T. The effect of propofol on increased superoxide concentration in cultured rat cerebrocortical neurons after stimulation of N-methyl-d-aspartate receptors. Anesth Analg 2002; 95:920-922
88. Holtkamp M, Tong X, Walker MC. Propofol in subanesthetic doses terminates status epilepticus in a rodent model. Ann Neurol 2001; 49:260-263
89. Lee VC, Moscicki JC, DiFazio CA. Propofol sedation produces dose-dependent suppression of lidocaine-induced seizures in rats. Anesth Analg 1998; 86:652-657
90. Momota Y, Artru AA, Powers KM, et al. Posttreatment with propofol terminates lidocaine-induced epileptiform electroencephalogram activity in rabbits: effects on cerebrospinal fluid dynamics. Anesth Analg 1998; 87:900-906
91. Hasan Z, Hasan M, al Hader A, et al. A comparison of the anticonvulsant effects of propofol and thiopentone against pentylenetetrazol-induced convulsions in the rat. Clin Exp Pharmacol Physiol 1991; 18:691-695
92. Lowson S, Gent JP, Goodchild CS. Anticonvulsant properties of propofol and thiopentone: comparison using two tests in laboratory mice. Br J Anaesth 1990; 64:59-63
93. Hantson P, Van Brandt N, Verbeeck R, et al. Propofol for refractory status epilepticus. Intensive Care Med 1994; 20:611-612
94. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29:1417-1425
95. Parke TJ, Stevens JE, Rice AS, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992; 305:613-616
96. Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002; 36:1453-1456
97. Branca D, Roberti MS, Lorenzin P, et al. Influence of the anesthetic 2,6-diisopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem Pharmacol 1991; 42:87-90
98. Branca D, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol (propofol) on isolated rat heart mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995; 110:41-45
99. Rigoulet M, Devin A, Averet N, et al. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. Eur J Biochem 1996; 241:280-285
100. Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med 2000; 28:172-177
101. McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003; 17:235-272
102. Short TG, Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17:77-89
103. Celesia G. Modern concepts of status epilepticus. JAMA 1976; 235:1571-1574
104. Dunne JW, Summers QA, Stewart-Wynne EG. Non-convulsive status epilepticus: a prospective study in an adult general hospital. Q J Med 1987; 62:117-126
105. Tomson T, Lindbom U, Nilsson BY. Nonconvulsive status epilepticus in adults: thirty-two consecutive patients from a general hospital population. Epilepsia 1992; 33:829-835
106. Cockerell OC, Walker MC, Sander JW, et al. Complex partial status epilepticus: a recurrent problem. J Neurol Neurosurg Psychiatry 1994; 57:835-837
107. Aminoff MJ. Do nonconvulsive seizures damage the brain? No. Arch Neurol 1998; 55:119-120
108. Kaplan PW. No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: "the cure may be worse than the disease"). Neurophysiol Clin 2000; 30:377-382
109. Kaplan PW. Assessing the outcomes in patients with non-convulsive status epilepticus: nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity. J Clin Neurophysiol 1999; 16:341-352
110. Kaplan PW. Prognosis in nonconvulsive status epilepticus. Epileptic Disord 2000; 2:185-193
111. Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003; 61:1066-1073